Expression of active human factor IX in mammary tissue of transgenic animals
    2.
    发明申请
    Expression of active human factor IX in mammary tissue of transgenic animals 失效
    活性人因子IX在转基因动物乳腺组织中的表达

    公开(公告)号:US20060287228A1

    公开(公告)日:2006-12-21

    申请号:US11117705

    申请日:2005-04-29

    摘要: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished using a chimeric construct comprising a mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5′-untranslated and 3′-untranslated region, which is substituted with a 5-′ and 3′-end of the mouse whey acidic protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and methods of producing Factor IX from such said culture and methods of treating hemophilia B are also described.

    摘要翻译: 可以在掺入根据本发明的嵌合DNA分子的转基因动物的乳中获得以高百分比的活性蛋白为特征的重组因子IX。 本发明的转基因动物通过引入编码因子IX的发育中的胚胎DNA而产生,使得外源DNA稳定地并入成熟动物的种系细胞的DNA中。 使用包含乳腺特异性启动子的嵌合构建体,缺乏5'和3'非翻译区的完整或任何部分的因子IX cDNA,其被5'和3' -end的小鼠乳清酸性蛋白基因。 还描述了从本发明的转基因哺乳动物移出的细胞的体外细胞培养物和从所述培养物生产因子IX的方法和治疗血友病B的方法。

    ORAL TREATMENT OF HEMOPHILIA
    3.
    发明申请
    ORAL TREATMENT OF HEMOPHILIA 有权
    海洛因口服治疗

    公开(公告)号:US20070179095A1

    公开(公告)日:2007-08-02

    申请号:US11734489

    申请日:2007-04-12

    IPC分类号: A61K38/37

    摘要: Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.

    摘要翻译: 本文公开了一种治疗抗原缺陷性疾病的简单方法,其通过口服给予受试者治疗有效量的缺陷抗原,其中所述抗原不存在于脂质体中。 在一个实施方案中,该方法通过口服给予血友病患者治疗有效量的除脂质体以外的适当的凝血因子,足以诱导口服耐受并向受试者提供外源性凝血因子来增加患有血友病A或B的受试者的止血 。